GERD prevalence in migraine patients and the implication for acute migraine treatment

被引:24
|
作者
Katic, Bozena J. [1 ]
Golden, Wendy [2 ]
Cady, Roger K. [3 ]
Hu, X. Henry [2 ]
机构
[1] Temple Univ, Sch Pharm, Ctr Pharmaceut Hlth Serv Res, Philadelphia, PA 19122 USA
[2] Merck & Co Inc, Global Outcomes Res, Whitehouse Stn, NJ USA
[3] Headache Care Ctr, Springfield, MO USA
关键词
Comorbidity; GERD; Migraine treatment; NSAID; Heartburn; Coprevalence; GASTROESOPHAGEAL-REFLUX DISEASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CLINICAL-DATA; POPULATION; SYMPTOMS; HEADACHE; NSAIDS; EPIDEMIOLOGY; COMORBIDITY; MECHANISMS;
D O I
10.1007/s10194-008-0083-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The objective of this study is to estimate the prevalence of gastroesophageal reflux disease (GERD) and heartburn in migraine patients and examine their use of non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin-containing medications when treating acute migraine attacks. Responses from a web-based survey of migraine patients were matched to the same patient's responses on a general health survey. A total of 1,832 migraineurs (92.0%) were successfully matched. A total of 403 migraineurs (22.0%) reported having diagnosed GERD, 212 (11.6%) reported diagnosed heartburn, and 290 (15.8%) reported reflux symptoms but were undiagnosed. The most common prescription drugs used to treat migraines were triptans. First-line NSAID/aspirin medication use was 10.0% among diagnosed GERD and heartburn patients, 17.8% among undiagnosed patients, and 11.8% among GERD/heartburn-free migraineurs. In conclusion, almost half of migraineurs reported physician-diagnosed GERD and heartburn or symptoms of these conditions. Use of NSAID medications for migraine is fairly common among diagnosed GERD patients and more so for those with undiagnosed GERD symptoms. Physicians should minimize prescribing NSAIDs or NSAID-containing acute migraine medications in this population.
引用
收藏
页码:35 / 43
页数:9
相关论文
共 50 条
  • [21] Prevalence and impact of visual aura in migraine and probable migraine: a population study
    Kim, Kyung Min
    Kim, Byung-Kun
    Lee, Wonwoo
    Hwang, Heewon
    Heo, Kyoung
    Chu, Min Kyung
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [22] Acute Treatment Optimization in Episodic and Chronic Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study
    Serrano, Daniel
    Buse, Dawn C.
    Adams, Aubrey Manack
    Reed, Michael L.
    Lipton, Richard B.
    HEADACHE, 2015, 55 (04): : 502 - 518
  • [23] Acute treatment of migraine: quo vadis?
    Martelletti, Paolo
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (11) : 1035 - 1037
  • [24] Increased prevalence of depression and anxiety in patients with migraine and interictal photophobia
    Llop, Stephanie
    Frandsen, Jonathan E.
    Digre, Kathleen B.
    Katz, Bradley J.
    Crum, Alison V.
    Zhang, Chong
    Warner, Judith E. A.
    JOURNAL OF HEADACHE AND PAIN, 2016, 17 : 1 - 7
  • [25] The prevalence of depression and the accuracy of depression screening tools in migraine patients
    Amoozegar, Farnaz
    Patten, Scott B.
    Becker, Werner J.
    Bulloch, Andrew G. M.
    Fiest, Kirsten M.
    Davenport, W. Jeptha
    Carroll, Christopher R.
    Jette, Nathalie
    GENERAL HOSPITAL PSYCHIATRY, 2017, 48 : 25 - 31
  • [26] Prevalence of Pulsatile Tinnitus Among Patients With Migraine
    Weinreich, Heather M.
    Carey, John P.
    OTOLOGY & NEUROTOLOGY, 2016, 37 (03) : 244 - 247
  • [27] Migraine and Mood Disorders: Prevalence, Clinical Correlations and Disability
    Rammohan, K.
    Mundayadan, Shyma Manikkoth
    Das, Soumitra
    Shaji, C. Velayudhan
    JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE, 2019, 10 (01) : 28 - 33
  • [28] Prevalence and Associated Factors of Depression among Adults Suffering from Migraine in Spain
    Cebrino, Jesus
    Portero de la Cruz, Silvia
    BRAIN SCIENCES, 2023, 13 (12)
  • [29] Acute Migraine Treatment in Adults
    Becker, Werner J.
    HEADACHE, 2015, 55 (06): : 778 - 793
  • [30] Lasmiditan for acute treatment of migraine
    Parikh, S.
    DRUGS OF TODAY, 2021, 57 (02) : 89 - 100